Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Open-Label, Multicenter Study Evaluating the Safety, Feasibility, and Preliminary Efficacy of ITIL-168 With Pembrolizumab in Subjects With Advanced Solid Tumors

Next Previous
Trial Profile

A Phase 1, Open-Label, Multicenter Study Evaluating the Safety, Feasibility, and Preliminary Efficacy of ITIL-168 With Pembrolizumab in Subjects With Advanced Solid Tumors

Status: Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 22 Dec 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ITIL-168 (Primary) ; Pembrolizumab (Primary)
  • Indications Cervical cancer; Head and neck cancer; Non-small cell lung cancer; Squamous cell cancer
  • Focus Adverse reactions
  • Acronyms DELTA-2
  • Sponsors Instil Bio

Most Recent Events

  • 16 Dec 2022 Status changed to withdrawn prior to enrolment.(business decision)
  • 14 Nov 2022 According to an Instil Bio media release, the company is deferring enrollment in the trial to focus resources toward higher-priority clinical programs.
  • 31 Oct 2022 According to an Instil Bio media release, the company intends to provide an update on the manufacturing analysis by early Q1 2023.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top